Erythropoietin
- Generic Name
- Erythropoietin
- Brand Names
- Procrit, Eprex, Epprex, Epoetin Alfa Hexal, Silapo, Biopoin, Abseamed, Eporatio, NeoRecormon, Epogen, Retacrit
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 11096-26-7
- Unique Ingredient Identifier
- 64FS3BFH5W
- Background
Erythropoietin (EPO) is a growth factor produced in the kidneys that stimulates the production of red blood cells. It works by promoting the division and differentiation of committed erythroid progenitors in the bone marrow . Epoetin alfa (Epoge) was developed by Amgen Inc. in 1983 as the first rhEPO commercialized in the United States, followed by other alf...
- Indication
用于肾功能不全合并的贫血，艾滋病本身或因治疗引起的贫血，恶性肿瘤伴发的贫血及风湿性贫血等。另外，为择期手术储存自体血而反复采血的患者，同时应用本品可预防发生贫血。
- Associated Conditions
- Anemia, Blood Loss During Surgery, Anemia caused by Zidovudine
- Associated Therapies
- -
Paricalcitol Improves Anemia of Inflammation
- First Posted Date
- 2016-08-23
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Hospital Son Espases
- Target Recruit Count
- 19
- Registration Number
- NCT02876211
- Locations
- 🇪🇸
Son Espases University Hospital, Palma de Mallorca, Islas Baleares, Spain
A Study of Epoetin Beta (NeoRecormon) in Anemic Participants With Diabetes and Chronic Renal Failure Who Are Not on Dialysis
- First Posted Date
- 2016-07-11
- Last Posted Date
- 2016-07-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 122
- Registration Number
- NCT02827266
High-dose Erythropoietin for Asphyxia and Encephalopathy
- Conditions
- Interventions
- First Posted Date
- 2016-06-23
- Last Posted Date
- 2023-01-30
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 500
- Registration Number
- NCT02811263
- Locations
- 🇺🇸
Children's Hospital of San Antonio, San Antonio, Texas, United States
🇺🇸Washington University, Saint Louis, Missouri, United States
🇺🇸Primary Children's Hospital, Salt Lake City, Utah, United States
EPOgen and Restrictive Transfusions in Patients Undergoing Cardiac Surgery (EPORT)
- Conditions
- Interventions
- First Posted Date
- 2016-06-16
- Last Posted Date
- 2019-02-26
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 4
- Registration Number
- NCT02802592
- Locations
- 🇺🇸
Suburban Hospital, Bethesda, Maryland, United States
A Study to Evaluate Efficacy and Safety of Epoetin Beta (NeoRecormon®) in Anemic Participants With Breast Cancer Undergoing Chemotherapy
- First Posted Date
- 2016-05-04
- Last Posted Date
- 2018-08-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 200
- Registration Number
- NCT02761642
A Study of Recormon (Epoetin Beta) in Anemic Patients With Non-Myeloid Malignancy
- First Posted Date
- 2015-12-08
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 10
- Registration Number
- NCT02624141
A Study to Assess the Hematopoyetic Response of Anemic Patients With Hematologic Malignancies Treated With Erythropoietin B
- First Posted Date
- 2015-11-18
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 4
- Registration Number
- NCT02608060
Neovascularization Induced by Mechanical Barrier disrUption and Systemic Erythropoietin in Patients With Cerebral Perfusion Deficits
- First Posted Date
- 2015-11-11
- Last Posted Date
- 2020-08-19
- Lead Sponsor
- Ajou University School of Medicine
- Target Recruit Count
- 44
- Registration Number
- NCT02603406
To Investigate the Pharmacokinetics of EPORON® and EPREX® After Subcutaneous Administration in Healthy Male Volunteers
- First Posted Date
- 2015-10-20
- Last Posted Date
- 2015-10-20
- Lead Sponsor
- Dong-A ST Co., Ltd.
- Target Recruit Count
- 42
- Registration Number
- NCT02580006
- Locations
- 🇰🇷
Seoul National University Hospital Clinical Trials Center, Seoul, Korea, Republic of
A Study of Epoetin Beta (NeoRecormon) in Predialysis Patients With Renal Anemia
- First Posted Date
- 2015-10-06
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 58
- Registration Number
- NCT02569515
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.